10-K: Arcturus Therapeutics Reports Progress in mRNA Medicines and Commercialization of KOSTAIVE in 2024

Arcturus Therapeutics transitions to a commercial-stage company with KOSTAIVE sales in Japan and advances its mRNA vaccine and therapeutic pipeline.

Summary

• Arcturus Therapeutics is focused on mRNA medicines, including infectious disease vaccines and treatments for rare liver and respiratory diseases.
• The company achieved its first commercial sales with KOSTAIVE, a COVID-19 vaccine approved in Japan in 2023, beginning in October 2024.
• KOSTAIVE also received approval from the European Commission in February 2025.
• Arcturus is collaborating with CSL Seqirus on mRNA vaccines for COVID-19, influenza, and other infectious diseases.
• A Phase 1 clinical trial for a seasonal influenza sa-mRNA vaccine candidate began in January 2024, and a Phase 1 trial for a pandemic avian influenza vaccine candidate began in December 2024, funded by BARDA.
• The company completed dosing in a Phase 2 study of ARCT-810 for OTC deficiency in August 2024 and initiated dosing in an open-label Phase 2 study in December 2024.
• Dosing also began in a Phase 2 study of ARCT-032 for cystic fibrosis in December 2024.
• Arcturus is exploring genome editing and new targeting approaches for its LUNAR and STARR platforms.
• The company has established commercial production processes for the COVID-19 vaccine program with CSL Seqirus.
• As of December 31, 2024, Arcturus had approximately 176 employees.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as the commercialization of KOSTAIVE and regulatory approvals, there are also significant financial losses and risks associated with the company's operations and competition.

Positives

• KOSTAIVE achieved approval in Japan in 2023 and commercial sales began in October 2024, marking Arcturus' transition to a commercial-stage company.
• KOSTAIVE received approval from the European Commission in February 2025, expanding its potential market.
• The company's LUNAR and STARR platforms have been validated by the approval of KOSTAIVE.
• Arcturus has a collaboration with CSL Seqirus, a leading influenza vaccine provider, for mRNA vaccines.
• The company has a contract with BARDA to support the development of a low-dose pandemic influenza candidate.
• ARCT-810 has received Orphan Drug Designation and Fast Track Designation from the FDA, as well as Orphan Medicinal Product Designation from the EMA.
• ARCT-032 has received Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the EMA.
• The company has a strong intellectual property portfolio with over 500 patents and pending patent applications.

Negatives

• The company has incurred significant losses since its inception, with an accumulated deficit of $448.8 million as of December 31, 2024.
• Arcturus has not generated any revenue from product sales, and has generated only limited collaboration and grant revenue since inception.
• The company is dependent on relationships with collaboration partners, and the failure of these relationships could negatively affect the business.
• KOSTAIVE only has marketing approval in Japan and Europe and may never achieve marketing approval in any other countries.
• There is significant competition in the development of a vaccine against COVID-19, and many competitors have substantially greater financial, scientific and other resources.
• The company has identified a material weakness in its internal control over financial reporting, and determined that its disclosure controls and procedures were not effective.

Risks

• The company may need to raise additional capital in the future, which may not be available on acceptable terms, or at all.
• The company is exposed to interest rate risk, including under its loan agreements.
• The company is highly dependent upon its relationship with CSL Seqirus to further research, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other infectious diseases.
• If the prevalence of COVID-19 and public concern about the virus continues to decline, the potential market opportunity will shrink for KOSTAIVE.
• If the company is unable to generate successful results from preclinical and clinical studies of its product candidates, or experience significant delays in doing so, its business may be materially harmed.
• If any of the product candidates cause undesirable side effects or have other properties impacting safety, their regulatory approval could be prevented, delayed or limited.
• If the contract manufacturers the company relies on to produce the supply of its preclinical and clinical product candidates do not timely deliver adequate quantities of quality materials, development and commercialization of the product candidates would be hindered.
• Claims that the company infringes the intellectual property rights of others, especially in the crowded and competitive field of mRNA patents, may prevent or delay the company's development and commercialization efforts.
• The company's business is subject to audit by the U.S. Government, and a negative audit could adversely affect the business.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it expands its development activities and advances its programs.

Industry Context

The RNA pipeline across the biopharma industry is expansive, with mostly early-stage assets. Competition is intensifying in this space as both biotech and larger pharma companies invest more in RNA technology and RNA pipelines mature.

Comparison to Industry Standards

• Arcturus faces competition from companies like Pfizer/BioNTech and Moderna, which have approved conventional mRNA-based COVID-19 vaccines.
• Genevant Sciences and Acuitas Therapeutics are also developing nucleic acid delivery platforms which compete with LUNAR technology.
• Ultragenyx is advancing a gene therapy program for OTC in clinical development, and Moderna has a therapeutic candidate in pre-clinical development, competing with ARCT-810.
• Moderna/Vertex, Eloxx Pharmaceuticals, Recode, 4DMT, Spirovant, SalioGen and Splisense are developing product candidates that compete with ARCT-032 for cystic fibrosis.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital by issuing equity securities.
• Employees may be affected by changes in compensation or benefits.
• Patients may benefit from the development of new mRNA medicines.
• Suppliers and manufacturers may be affected by changes in the company's supply chain.

Next Steps

• Continue Phase 2 trial of ARCT-810.
• Advance LUNAR-CF program in clinical trials.
• Continue exploratory activities related to the platform.
• Execute on milestones within the CSL Collaboration Agreement.

Key Dates

Keywords

mRNA, vaccines, KOSTAIVE, LUNAR, STARR, CSL Seqirus, clinical trials, COVID-19, influenza, OTC deficiency, cystic fibrosis, ARCT-810, ARCT-032, BARDA, intellectual property